- Home
- / OSE Immunotherapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
OSE Immunotherapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
€10
2024-10-29
Market Capitalization
€221.3 M
2024-10-29
Revenue
€69.9 M
FY, 2024
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.5M | 26.0M | 10.4M | 26.3M | 18.3M | 2.2M | 69.9M |
| Gross profit | 24.5M | 26.0M | 10.4M | 26.3M | 18.3M | 2.2M | 83.4M |
| Gross profit margin, % | 100.0% | 100.0% | 100.1% | 100.0% | 100.0% | 100.0% | 119.4% |
| Operating expense total | 19.5M | 26.9M | 28.7M | 40.2M | 33.1M | 21.8M | 36.5M |
| Depreciation and amortization | 14.0K | 482.0K | 730.0K | 2.7M | 3.6M | 3.5M | 3.4M |
| EBITDA | 5.0M | (989.0K) | (18.3M) | (13.9M) | (14.8M) | (19.5M) | 47.1M |
| EBITDA margin, % | 20.3% | -3.8% | -175.3% | -53.0% | -81.1% | -873.8% | 67.4% |
| EBIT | 4.8M | (1.5M) | (19.0M) | (16.6M) | (18.5M) | (23.0M) | 43.7M |
| EBIT margin, % | 19.8% | -5.7% | -182.3% | -63.2% | -101.0% | -1032.1% | 62.6% |
| Interest income | 40.0K | ||||||
| Interest expense | 212.0K | 192.0K | 273.0K | 836.0K | 1.4M | 2.3M | 3.3M |
| Pre tax profit | 4.7M | (1.5M) | (19.2M) | (17.2M) | (18.0M) | (23.2M) | 39.8M |
| Income tax expense | (783.0K) | 3.2M | (2.7M) | (364.0K) | (263.0K) | (219.0K) | 2.4M |
| Net Income | 5.5M | (4.7M) | (16.6M) | (16.8M) | (17.8M) | (23.0M) | 37.4M |